Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co LtdfiledCriticalHanmi Pharm Ind Co Ltd
Publication of ECSP11011251ApublicationCriticalpatent/ECSP11011251A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención se relaciona con una composición farmacéutica sólida para la prevención y tratamiento de desórdenes cardiovasculares que comprenden formas granulares de amlodipina y losartan las cuales separadas la una de la otra, y un agente estabilizador, el cual ha mejorado la estabilidad de almacenamiento debido a interacción minimizada entre la amlodipina y el losartan.The present invention relates to a solid pharmaceutical composition for the prevention and treatment of cardiovascular disorders comprising granular forms of amlodipine and losartan which separated from each other, and a stabilizing agent, which has improved storage stability due to minimized interaction between amlodipine and losartan.
ECSP110112512009-01-232011-08-09
SOLID PHARMACEUTICAL COMPOSITION THAT INCLUDES AMLODIPINE AND LOSARTAN WITH IMPROVED STABILITY.
ECSP11011251A
(en)
Composition for use in brain growth and / or cognitive development and / or psychomotor development comprising at least one long chain polyunsaturated fatty acid (lc-pufa), at least one probiotic and a mixture of oligosaccharides; Use of the composition.
COMPOUNDS DERIVED FROM DIHIDRO AND TETRAHIDRO OXAZOLOPIRIMIDINONAS REPLACED; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE FOR THE TREATMENT OF CHICHOPHRENIA, EPILEPSY, BETWEEN OTHER DISEASES.
A prodrug composition comprising at least one methylphenidate conjugate; pharmaceutical kit that includes it, useful for the treatment of a disease or condition that requires stimulation of the nervous system such as a hyperactivity disorder with attention deficit and depression.
2-Oxo-1-pyrrolidinyl-imidazothiadiazole derived compounds; pharmaceutical composition comprising them; useful for the treatment of epilepsy, neurological disorders, among others.
Compounds derived from pyrimido- [4,5-b] -quinoline-4,5 (3h, 10h) -diones to be used as a medicament for the treatment of a disease caused by a nonsense mutation; composition and pharmaceutical combination that includes them.